Max Planck Seminar: Hannah Uckelmann - Targeting chromatin regulators during leukemia development

Dr. Hannah Uckelmann is Max-Eder junior research group leader at University Hospital Goethe Universität Frankfurt, Germany. Her lab focuses on studying the epigenetic regulation of self-renewal programs during cancer development and the discovery of new therapeutics. Hannah discovered an unexpected role of mutant NPM1 on chromatin representing the molecular basis for the effectiveness of targeted epigenetic therapies in NPM1 mutant AML. NPM1c cooperates with other chromatin factors to change the chromatin landscape and enhance transcriptional output at its target sites. She and her team continued investigating NPM1c-driven leukemogenesis with focus on novel therapeutic therapies in NPM1 mutant AML.